Sight Sciences (SGHT) Q1 2025: $4M Tariff Headwind Drives Cost Discipline and Manufacturing Shift
Sight Sciences faces a dual-front challenge as new China tariffs threaten gross margins and Medicare restrictions reshape the MIGS market, yet management responds with swift cost controls and manufacturing relocation plans. The quarter’s results underscore resilience in core glaucoma accounts, but dry eye reimbursement remains a pivotal catalyst for future upside. Investors should watch tariff mitigation and payer decisions as critical swing factors for the year.
Summary
- Tariff Impact Forces Action: New 145% China tariffs will raise costs, prompting rapid expense cuts and a shift to alternative manufacturing.
- MIGS Market Adapts to Medicare Rule: Single-procedure reimbursement restricts volumes, but Omni’s comprehensive efficacy retains surgeon loyalty.
- Dry Eye Upside Hinges on Reimbursement: TearCare remains subdued until payer coverage lands, with 2025 decisions a key swing event.
Performance Analysis
Sight Sciences delivered Q1 revenue of $17.5 million, reflecting a 9% year-over-year decline as the company absorbed the full effect of Medicare’s new restriction on multiple MIGS (minimally invasive glaucoma surgery) procedures. Surgical glaucoma accounted for $17.1 million—over 97% of total revenue—down 6% year-over-year, driven by a 10% drop in account utilization as physicians adjust to the one-procedure rule. Yet, ordering accounts grew 3% versus last year, signaling that core customer retention remains solid even as procedure volume per account dips.
Dry eye revenue fell to $0.4 million from $1 million a year ago, reflecting fewer SmartLids sold after a price increase aimed at supporting future reimbursement economics for TearCare, the company’s interventional dry eye procedure. Gross margin held steady at 86%, shielded in Q1 by pre-tariff inventory, but management flagged a coming $3.5–$4.5 million cost of goods sold (COGS) headwind for the full year as 145% China tariffs take hold. Operating expenses fell 7%, with further cuts planned to offset tariff-driven COGS inflation. The net loss narrowed to $14.2 million, aided by disciplined spending and lower legal fees.
- Tariff Exposure Emerges: China tariff hikes will materially raise COGS, impacting margins until manufacturing relocates.
- Utilization Down, Accounts Stable: Lower volumes per account offset by resilient customer base in surgical glaucoma.
- Dry Eye Revenue Suppressed: TearCare sales await payer coverage decisions, with only modest revenue expected until then.
Cash burn was $11.6 million in Q1, including annual bonuses, leaving $108.8 million in cash and $40 million in debt. The company reaffirmed full-year revenue guidance of $70–$75 million, with dry eye expected to contribute $1 million absent reimbursement wins.
Executive Commentary
"As most of our products are manufactured and assembled in China, we expect increases to our cost of goods sold starting in the second quarter of 2025 and throughout 2025 for as long as these tariffs remain in effect. We expect to mostly offset the incremental tariff costs with reductions in our operating expenses."
Paul Badawi, Co-founder and Chief Executive Officer
"At the current 145% China tariff rate and based on current revenue expectations including product mix and related inventory on hand, our surgical glaucoma segment unmitigated tariff exposure would increase the segment's cost of goods sold by between approximately $3.5 million and $4.5 million for full year 2025. The impact is expected to be larger in the second half of 2025 versus the first half of 2025."
Aoi Bowerly, Chief Financial Officer
Strategic Positioning
1. Tariff Mitigation and Manufacturing Relocation
Management is executing a rapid response to tariff-driven cost inflation. With most products currently manufactured in China, the new 145% tariff will materially pressure gross margin beginning in Q2. To counter this, Sight Sciences is establishing third-party manufacturing outside China, initially for the OmniEdge product, with new lines expected in 9–12 months and further capacity phased in over the next 6–9 months. Setup costs are minimal, and future manufacturing costs (excluding tariffs) are projected to be comparable to current levels.
2. Navigating the New MIGS Market
The surgical glaucoma franchise, anchored by Omni, faces a reshaped competitive landscape after Medicare’s restriction on multiple MIGS procedures. Omni’s FDA indication for two sequential procedures in a single device—canaloplasty and trabeculotomy—positions it as a comprehensive solution for surgeons now forced to pick a single option. Customer engagement and education are central to retaining and growing share, as Sight Sciences leverages Omni’s clinical efficacy and broad surgeon training footprint (about half of all MIGS-trained surgeons in the US).
3. Dry Eye: Awaiting Reimbursement Inflection
TearCare’s market opportunity remains largely untapped until payer coverage is achieved. Management continues payer engagement, armed with strong clinical evidence (Sahara RCT) and a growing installed base (65,000 procedures, 1,500 trained providers). Coverage decisions are targeted for 2025, with upside to financials if positive determinations materialize. Until then, revenue will remain modest, though the infrastructure is in place for rapid scaling.
4. Product Innovation and Portfolio Expansion
The recent launch of OmniEdge, featuring proprietary TruSync technology for enhanced visco-dilation, is intended to address evolving surgeon preferences and extend the Omni platform’s reach. Early feedback from key opinion leaders has been positive, supporting the company’s strategy to offer a differentiated, multi-modal MIGS solution.
Key Considerations
The quarter’s results reflect a business in transition, with macro and regulatory shocks driving both risk and opportunity across the portfolio.
Key Considerations:
- Tariff Headwind Timing: COGS inflation will accelerate in the second half as pre-tariff inventory is depleted, making expense discipline critical.
- Omni’s Market Position: The device’s multi-mechanistic design is a structural advantage in the new one-procedure MIGS environment, but utilization per account remains a watchpoint.
- Dry Eye Leverage: TearCare’s upside is binary, hinging on payer decisions; infrastructure is built for scale, but revenue is gated by reimbursement.
- Competitive Dynamics: New entrants and product launches (e.g., New World’s Via360) are being monitored, but Omni’s clinical reputation and ease of use remain differentiators.
- Cash Runway and Capital Allocation: With over $100 million in cash, the company has flexibility, but sustained losses and tariff-driven margin pressure could test discipline if reimbursement timelines slip.
Risks
Tariff persistence represents a material risk to gross margin if manufacturing relocation is delayed or tariffs remain elevated into 2026. The company’s revenue remains highly concentrated in surgical glaucoma, making it vulnerable to further regulatory or competitive shocks. Dry eye upside is not in guidance and could disappoint if payer decisions are delayed. Execution risk around manufacturing transition and cost controls is elevated given the pace of change.
Forward Outlook
For Q2 2025, Sight Sciences expects:
- Surgical glaucoma revenue down high single digits to low double digits year-over-year
- Dry eye revenue to remain modest, pending reimbursement outcomes
For full-year 2025, management reaffirmed:
- Revenue guidance of $70–$75 million
- Adjusted operating expenses of $101–$105 million (lowered from prior range)
Management highlighted that tariff impact will be most acute in the second half, with offsetting expense cuts in place. Dry eye revenue is not expected to accelerate absent positive payer decisions. Manufacturing relocation for OmniEdge is on track for late 2025, with further capacity phased in through mid-2026.
- Tariff mitigation and manufacturing transition are top operational priorities
- Dry eye reimbursement remains a key potential catalyst for upside
Takeaways
Investors should focus on SGHT’s ability to absorb tariff-driven cost inflation, retain share in a reshaped MIGS market, and catalyze dry eye upside through payer wins.
- Tariff and COGS Management: Timely execution of manufacturing relocation is essential to restore margin stability and protect the cash runway.
- Omni Retention Critical: Despite lower utilization, account retention and product innovation give SGHT a competitive edge in the evolving MIGS space.
- Dry Eye as Binary Catalyst: The pace and outcome of payer coverage for TearCare will dictate whether dry eye becomes a growth engine or remains a drag.
Conclusion
Sight Sciences is navigating a challenging external environment with decisive cost management and a clear strategy to mitigate tariff and regulatory headwinds. The next 12 months will be defined by tariff mitigation, manufacturing execution, and the timing of dry eye reimbursement—a trio of levers that will determine the company’s ability to return to growth and margin expansion.
Industry Read-Through
The material impact of China tariffs on SGHT’s COGS is a cautionary signal for other medtechs with China-based manufacturing, especially those lacking geographic redundancy. The rapid shift in Medicare reimbursement for MIGS also highlights the vulnerability of procedure-driven device markets to policy changes, reinforcing the need for portfolio diversity and payer engagement. The slow pace of payer adoption for interventional dry eye procedures underlines the long lead times required for category creation, even with strong clinical evidence. Peers in ophthalmology and broader medtech should monitor tariff exposure, reimbursement risk, and the importance of building scalable, flexible supply chains.